Allergy medication acts in two pathways — the histamine pathway and the inflammatory (leukotriene/cytokine) pathway — to control both the immediate and sustained phases of allergic reactions. When the immune system overreacts to allergens such as pollen, pet dander, or food proteins, it triggers a rapid histamine-driven response followed by a slower inflammatory cascade involving leukotrienes and cytokines. Understanding how these two pathways work helps explain why different treatments are used for different conditions, why combination therapy is sometimes necessary, and how newer biologic medicines target the underlying disease process rather than simply relieving symptoms.

How Allergy Medications Target Two Pathways in the Immune Response

When the immune system encounters an allergen — whether pollen, pet dander, a food protein, or a drug — it triggers a cascade of biological events designed to neutralise the perceived threat. In allergic individuals, this response is exaggerated and causes the familiar symptoms of sneezing, itching, swelling, and in severe cases, anaphylaxis. Understanding how allergy medication acts across two broad pathways is a useful educational framework for explaining why different treatments are used for different conditions, and why some patients require combination therapy.

The two principal pathways targeted by allergy medications are the histamine pathway and the inflammatory (leukotriene/cytokine) pathway. The first involves the rapid release of histamine from mast cells and basophils, producing immediate symptoms. The second involves a slower, sustained inflammatory response driven by chemical mediators such as leukotrienes, prostaglandins, and cytokines. Together, these pathways account for both the early-phase and late-phase allergic reactions.

It is important to note that this 'two-pathway' framing is a teaching simplification rather than an official framework endorsed by NICE or the NHS. In practice, allergy management is condition-specific and guided by a range of UK clinical resources, including NICE Clinical Knowledge Summaries (CKS) for allergic rhinitis and urticaria, the BTS/SIGN British Guideline on the Management of Asthma, and BSACI specialty guidelines. Some treatments — such as anti-IgE biologics and allergen immunotherapy — act upstream of both pathways and can modify the underlying disease process rather than simply relieving symptoms.

The Histamine and Inflammatory Pathways Explained

The histamine pathway is the more immediately recognisable of the two. When an allergen binds to immunoglobulin E (IgE) antibodies on the surface of mast cells (via the high-affinity IgE receptor, FcεRI), these cells degranulate and release histamine into surrounding tissues within minutes. Histamine then binds to H1 receptors found throughout the body — in the skin, nasal mucosa, eyes, and airways — producing vasodilation, increased vascular permeability, smooth muscle contraction, and nerve stimulation. This accounts for symptoms such as urticaria (hives), rhinorrhoea, conjunctival redness, and bronchospasm. This early-phase reaction typically peaks within 15–30 minutes of allergen exposure.

The inflammatory pathway operates on a different timescale and involves a broader range of mediators. Following the early histamine-driven response, arachidonic acid is metabolised via the lipoxygenase and cyclooxygenase enzymes to produce leukotrienes and prostaglandins respectively. Leukotrienes — particularly LTC4, LTD4, and LTE4 — are potent bronchoconstrictors and also promote mucus secretion and eosinophil recruitment. This late-phase inflammatory response typically develops 4–8 hours after allergen exposure and can persist for hours or even days, contributing to chronic symptoms in conditions such as allergic rhinitis and asthma.

In many airway diseases, including allergic asthma and severe atopic conditions, type-2 inflammation — characterised by elevated IL-4, IL-5, and IL-13, along with eosinophil accumulation — is the dominant sustained mechanism rather than histamine alone. Cytokines such as IL-4, IL-5, and IL-13 sustain the inflammatory pathway, particularly in more severe or refractory allergic disease. Newer biologic therapies are specifically designed to interrupt this signalling: dupilumab targets the shared IL-4/IL-13 receptor (IL-4Rα), whilst anti-IL-5 agents (mepolizumab, reslizumab) and anti-IL-5 receptor agents (benralizumab) reduce eosinophilic inflammation in severe asthma. Tezepelumab, an anti-TSLP biologic, acts even further upstream by blocking thymic stromal lymphopoietin, a key initiator of type-2 inflammation. Understanding both pathways — and the upstream mechanisms that drive them — is essential for appreciating why a single medication class is often insufficient for complex allergic conditions.

Types of Allergy Medication Available on the NHS

The NHS provides access to a range of allergy medications that act across both pathways, available either over the counter or on prescription depending on the indication and severity.

Targeting the histamine pathway:

• Antihistamines (H1 receptor antagonists) are the most widely used first-line treatment for mild-to-moderate allergic symptoms. Second-generation antihistamines such as cetirizine, loratadine, and fexofenadine are preferred due to their non-sedating profile and once-daily dosing. First-generation antihistamines (e.g., chlorphenamine) may be used for acute allergic reactions such as urticaria, but carry a higher risk of sedation and anticholinergic effects. Important: in anaphylaxis, adrenaline (epinephrine) is always the first-line treatment; antihistamines are adjunctive only and must never replace or delay adrenaline.

• Topical antihistamines, such as azelastine nasal spray or eye drops, provide localised relief for rhinitis and conjunctivitis.

• Mast-cell stabilisers, such as sodium cromoglicate (available as eye drops, nasal spray, and inhaler), prevent mast-cell degranulation and can be useful for mild allergic conjunctivitis and rhinitis, particularly in children.

Targeting the inflammatory pathway:

• Intranasal corticosteroids (e.g., fluticasone, mometasone, beclometasone) reduce eosinophilic inflammation in the nasal mucosa and are recommended by NICE CKS as first-line treatment for moderate-to-severe allergic rhinitis.

• Leukotriene receptor antagonists such as montelukast block the action of cysteinyl leukotrienes. In the UK, montelukast is licensed for the treatment of asthma and, in patients who also have asthma, for the relief of symptoms of seasonal allergic rhinitis. It is not licensed as a standalone treatment for allergic rhinitis in patients without asthma. See the safety note below regarding neuropsychiatric effects.

• Inhaled corticosteroids (e.g., beclometasone, budesonide, fluticasone) are central to asthma management and act broadly on the inflammatory pathway.

• Short-term nasal decongestants (e.g., xylometazoline) may provide temporary relief of nasal congestion but should not be used for more than 5–7 days due to the risk of rebound congestion (rhinitis medicamentosa). Intranasal ipratropium bromide may be used for rhinorrhoea that is predominantly watery and unresponsive to other treatments.

• Biologics available on the NHS for severe, refractory disease under specialist supervision include:

• Omalizumab (anti-IgE): licensed for severe allergic asthma and chronic spontaneous urticaria (CSU) refractory to antihistamines.
• Dupilumab (anti-IL-4Rα): licensed for severe atopic dermatitis, severe asthma with type-2 inflammation, and chronic rhinosinusitis with nasal polyps. After specialist initiation, patients may self-administer dupilumab at home.
• Mepolizumab and benralizumab (anti-IL-5/IL-5R): licensed for severe eosinophilic asthma.
• Tezepelumab (anti-TSLP): licensed for severe asthma as an add-on maintenance treatment.

For drug-specific dosing, contraindications, and administration details, refer to the relevant Summary of Product Characteristics (SmPC) or the British National Formulary (BNF).

Patients should report suspected side effects from any medication via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Choosing the Right Treatment Based on Your Symptoms

Selecting the most appropriate allergy medication depends on several factors: the type of allergen, the organs affected, the severity and frequency of symptoms, and whether the condition is intermittent or persistent. UK clinical decision-making is supported by NICE CKS (for allergic rhinitis, urticaria, and atopic eczema), the BTS/SIGN British Guideline on the Management of Asthma, and BSACI specialty guidelines.

For mild, intermittent symptoms such as occasional sneezing or itchy eyes during pollen season, a non-sedating oral antihistamine taken as needed is usually sufficient. These primarily target the histamine pathway and are effective for early-phase reactions.

For moderate-to-severe or persistent symptoms, particularly nasal congestion and post-nasal drip, an intranasal corticosteroid is recommended as first-line therapy by NICE CKS. These address the inflammatory pathway and are more effective than antihistamines alone for nasal blockage. A combination of both an antihistamine and an intranasal corticosteroid may be appropriate when symptoms span both pathways.

Patients with allergic asthma should follow a stepwise approach as outlined in the BTS/SIGN guideline. An inhaled corticosteroid (ICS) is the cornerstone of preventer therapy. A long-acting beta-agonist (LABA) is typically added before or alongside a leukotriene receptor antagonist (LTRA) if symptoms remain uncontrolled. Montelukast may be a useful add-on, particularly in patients with coexisting rhinitis and asthma — a recognised clinical overlap sometimes referred to as the 'united airway' concept. The MHRA issued updated guidance in 2020 regarding neuropsychiatric side effects associated with montelukast, including sleep disturbances, anxiety, depression, and suicidal ideation. Prescribers are required to discuss these risks with patients and carers before initiating treatment, and the medication should be discontinued if such symptoms emerge.

For skin-related allergic conditions such as urticaria, antihistamines (including higher-than-standard licensed doses under specialist guidance for chronic spontaneous urticaria, as per NICE CKS) address itch via the histamine pathway. For atopic eczema, the primary treatments are regular emollients and topical anti-inflammatory agents (topical corticosteroids or calcineurin inhibitors); antihistamines have a limited role and are not routinely recommended for itch in eczema. A short course of a sedating antihistamine may occasionally be considered for severe nocturnal itch affecting sleep, as per NICE CKS guidance. In severe or refractory cases, biologics such as dupilumab address the inflammatory component.

Always consult a GP or pharmacist before combining treatments.

Possible Side Effects and Safety Considerations

All allergy medications carry a potential for side effects, and patients should be aware of these before starting treatment. The safety profile varies considerably between drug classes and between individual agents within the same class.

Antihistamines:

• First-generation antihistamines (e.g., chlorphenamine) commonly cause drowsiness, dry mouth, urinary retention, and blurred vision due to their anticholinergic properties. They should be used with caution in elderly patients. Patients must not drive, operate machinery, or drink alcohol whilst taking sedating antihistamines.

• Second-generation antihistamines are generally well tolerated, though cetirizine may cause mild sedation in some individuals. Fexofenadine has the lowest sedation risk among commonly used agents. Note that fexofenadine absorption can be significantly reduced by grapefruit, orange, and apple juice; these should be avoided around the time of dosing.

Intranasal corticosteroids:

• Generally considered safe for long-term use at recommended doses. Common side effects include nasal dryness, epistaxis (nosebleeds), and throat irritation. To minimise the risk of nosebleeds, patients should direct the spray away from the nasal septum (towards the outer wall of the nostril). Systemic absorption is minimal at recommended doses, though prolonged high-dose use warrants monitoring, particularly in children.

Leukotriene receptor antagonists (montelukast):

• The MHRA (2020) has highlighted the risk of neuropsychiatric reactions, including sleep disturbances, anxiety, depression, and suicidal ideation. Patients and carers must be counselled about these risks before starting treatment, and the medication should be discontinued if such symptoms emerge. Report any suspected reactions via the Yellow Card scheme.

Biologics:

• Administered under specialist supervision. Omalizumab carries a risk of anaphylaxis; monitoring requirements and observation periods following injection should follow the current SmPC and local clinical protocol. Dupilumab may cause injection-site reactions and conjunctivitis; patients experiencing eye symptoms should seek advice from their specialist or GP.

Patients should always inform their GP or pharmacist of all medications they are taking, including over-the-counter products, to avoid interactions. Pregnant or breastfeeding women should seek specific advice before using any allergy medication, as safety data varies between agents; consult the relevant SmPC or a pharmacist for guidance.

Suspected adverse drug reactions should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

When to Seek Further Advice from a GP or Allergy Specialist

Whilst many allergic conditions can be managed effectively with over-the-counter treatments, there are important circumstances in which professional medical advice should be sought promptly.

Contact your GP if:

• Symptoms are not adequately controlled after 2–4 weeks of appropriate over-the-counter treatment

• You experience significant side effects from your current medication

• Symptoms are affecting your sleep, work, or quality of life

• You develop new symptoms such as wheeze, chest tightness, or shortness of breath, which may indicate allergic asthma

• You are pregnant, breastfeeding, or managing a child's allergy symptoms

• You have asthma that remains poorly controlled despite treatment

• You have chronic urticaria that does not respond to standard-dose antihistamines

For urgent medical advice that is not a life-threatening emergency, contact NHS 111 (online at 111.nhs.uk or by telephone).

Seek emergency medical attention — call 999 immediately — if you experience signs of anaphylaxis, including:

• Sudden swelling of the lips, tongue, or throat

• Difficulty breathing or swallowing

• Rapid heartbeat, dizziness, or collapse

• A widespread skin rash combined with any of the above

If you have been prescribed an adrenaline auto-injector (e.g., EpiPen or Jext), use it immediately at the first signs of anaphylaxis, then call 999. Do not wait to see if symptoms improve before using it.

Referral to an NHS allergy specialist (allergist or clinical immunologist) may be appropriate for patients with:

• Severe, complex, or poorly controlled allergic disease

• Severe or recurrent anaphylaxis

• Suspected food, drug, or venom allergy requiring formal investigation

• Refractory chronic spontaneous urticaria

• Consideration of allergen immunotherapy (desensitisation)

• Cases where the causative allergen has not been identified

Allergen immunotherapy — available as subcutaneous injections or sublingual tablets/drops — can modify the underlying allergic disease and is recommended by BSACI for selected patients with allergic rhinitis, allergic asthma, and insect venom allergy. Allergy testing, including skin prick tests and specific IgE blood tests, can help clarify the diagnosis and guide long-term management.

It is also worth noting that not all nasal or skin symptoms are caused by allergy; conditions such as non-allergic rhinitis or contact dermatitis require a different treatment approach. A thorough clinical assessment ensures the most appropriate and safe management plan is put in place.

Frequently Asked Questions